HOME >> BIOLOGY >> NEWS
Disease Mechanism In Hereditary Dementia Discovered: Treatment Implications Seen For Alzheimer's And Other Neurodegenerative Diseases

A new study led by scientists at the University of Pennsylvania Medical Center reveals pivotal characteristics of the disease mechanism underlying a hereditary dementia similar to and often confused clinically with Alzheimer's disease. With a clearer view of the pathology involved, the development of drug therapies to counter the problem becomes possible. Indeed, candidate compounds are already being appraised in the laboratory for their therapeutic potential.

A report on the study appears in the December 4 issue of Science.

The research team investigated a dementia linked to more than 10 different genetic flaws on chromosome 17 known as frontotemporal dementia and parkinsonism (FTDP-17). They found that, in FTDP-17, mutant versions of a protein called tau are unable to fulfill one of the protein's crucial roles, which is to stabilize structural elements in neurons called microtubules. In addition to shoring up the scaffolding of a cell, microtubules also form the basis of an intracellular transport system -- especially important in neurons, which have extensions called axons that can reach a full meter through the body. With microtubule assembly disrupted, these cells can die.

"The bottom line here is that there is loss of tau function with these mutations, and the function of tau is to stabilize microtubules," says Virginia M.-Y. Lee, PhD, a professor of pathology and laboratory medicine and senior author on the study. "In neurons, with their long, delicate axons, microtubules are extremely important not only as structural entities but also as a kind of railroad along which the cells move various materials critical to their survival."

The tau protein is also the main component of the abnormal tangles in neurons that, along with amyloid plaques, define Alzheimer's disease. Tau tangles are seen in other dementing diseases, too, such as Pick's disease. Prior to this study, however, scientists had been unable to
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
3-Dec-1998


Page: 1 2 3

Related biology news :

1. Disease diagnosis, drug development focus of UH profs biochip research
2. Disease-resistant papaya saves Hawaiian papaya industry
3. APS Inflammatory Bowel Diseases Translational Research Conference, Sept. 8-11
4. 1st International Conference on Cell Therapy for Cardiovascular Disease
5. Disease threatens cucumbers, pumpkins, and other vine crops
6. Disease-fighters in our mouths provide clues to enhancing the immune system
7. International Conference on Emerging Infectious Diseases
8. NIH establishes Rare Diseases Clinical Research Network
9. Shedding Light on Disease: A Briefing for Journalists
10. Disease-causing genetic mutations in sperm increase with mens age
11. World Congress on Huntingtons Disease to meet in Toronto, August 16-19, 2003

Post Your Comments:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: